{
    "Trade/Device Name(s)": [
        "Access Thyroglobulin Antibody II"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K240996",
    "Predicate Device Reference 510(k) Number(s)": [
        "K213517"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JNL"
    ],
    "Summary Letter Date": "July 3, 2024",
    "Summary Letter Received Date": "April 11, 2024",
    "Submission Date": "July 2, 2024",
    "Regulation Number(s)": [
        "21 CFR 866.5870"
    ],
    "Regulation Name(s)": [
        "Thyroid Autoantibody Immunological Test System"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "Thyroglobulin Antibody"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Access Immunoassay System",
        "DxI 9000 Access Immunoassay Analyzer",
        "Access 2 Immunoassay System"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay",
        "Paramagnetic particle",
        "Automated sandwich immunoassay"
    ],
    "Methodologies": [
        "Immunoenzymatic two-step sandwich assay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Beckman Coulter Access Thyroglobulin Antibody II immunoassay for quantitative detection of thyroglobulin antibodies in serum and plasma",
    "Indications for Use Summary": "Quantitative determination of thyroglobulin antibody levels in human serum and plasma to aid in diagnosis of Hashimoto's disease, nontoxic goiter, and Graves' disease",
    "fda_folder": "Immunology"
}